The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Urologic Neoplasms

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Urologic Neoplasms


High impact information on Urologic Neoplasms

  • MSH2 mutation carriers were found to have a significantly higher risk of developing cancer of the urinary tract (P < .05) [5].
  • Tissue-specific markers in flow cytometry of urological cancers. II. Cytokeratin and vimentin in renal-cell tumors [6].
  • Wave heights for sera from patients with untreated urological cancers significantly exceed those from normal subjects [7].
  • In particular, a thorough review of the current literature and recent abstract presentations at scientific meetings was done regarding the potential role of COX-2 in urological cancers (MEDLINE from 1960 to the present, and American Urological Association and American Society of Clinical Oncology annual meeting abstracts from1998 to the present) [8].
  • Roughly half of all human malignancies, including many urological cancers, exhibit p53 mutations [9].

Chemical compound and disease context of Urologic Neoplasms


Biological context of Urologic Neoplasms


Anatomical context of Urologic Neoplasms

  • These results indicate that the adenovirus-mediated expression of a soluble VEGF receptor can be an effective therapy for urological cancer treatment; however, such VEGF-targeted gene therapy is not necessarily accompanied by subsequent antitumor T cell immunity [16].

Gene context of Urologic Neoplasms


Analytical, diagnostic and therapeutic context of Urologic Neoplasms


  1. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. Pavone-Macaluso, M., de Voogt, H.J., Viggiano, G., Barasolo, E., Lardennois, B., de Pauw, M., Sylvester, R. J. Urol. (1986) [Pubmed]
  2. Ibandronate in metastatic bone pain. Heidenreich, A., Ohlmann, C., Body, J.J. Semin. Oncol. (2004) [Pubmed]
  3. Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladder. Maru, A., Akaza, H., Isaka, S., Koiso, K., Kotake, T., Machida, T., Matsumura, Y., Nakagami, Y., Niijima, T., Obata, K. Cancer Chemother. Pharmacol. (1987) [Pubmed]
  4. Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Wu, W.J., Kakehi, Y., Habuchi, T., Kinoshita, H., Ogawa, O., Terachi, T., Huang, C.H., Chiang, C.P., Yoshida, O. Jpn. J. Cancer Res. (1995) [Pubmed]
  5. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. Vasen, H.F., Stormorken, A., Menko, F.H., Nagengast, F.M., Kleibeuker, J.H., Griffioen, G., Taal, B.G., Moller, P., Wijnen, J.T. J. Clin. Oncol. (2001) [Pubmed]
  6. Tissue-specific markers in flow cytometry of urological cancers. II. Cytokeratin and vimentin in renal-cell tumors. Feitz, W.F., Karthaus, H.F., Beck, H.L., Romijn, C., van der Meyden, A.P., Debruyne, F.M., Vooijs, G.P., Ramaekers, F.C. Int. J. Cancer (1986) [Pubmed]
  7. Differential pulse polarography of the catalytic waves in serum from patients with urological cancers. Lyons, H., Adams, J.R., Jordan, W.P. Clin. Chem. (1982) [Pubmed]
  8. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. Pruthi, R.S., Derksen, E., Gaston, K. J. Urol. (2003) [Pubmed]
  9. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. Smith, N.D., Rubenstein, J.N., Eggener, S.E., Kozlowski, J.M. J. Urol. (2003) [Pubmed]
  10. Conventional and high dose cis-platinum in urological cancer. Javadpour, N. J. Urol. (1984) [Pubmed]
  11. Ifosfamide in urologic cancer. Boccardo, F., Guglielmini, P. Oncology (2003) [Pubmed]
  12. Prognostic value of host immunocompetence in urologic cancer patients. Catalona, W.J., Smolev, J.K., Harty, J.I. J. Urol. (1975) [Pubmed]
  13. The 4th study of prophylactic intravesical chemotherapy with adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese Urological Cancer Research Group for Adriamycin. Matsumura, Y., Akaza, H., Isaka, S., Kagawa, S., Koiso, K., Kotake, T., Machida, T., Niijima, T., Obata, K., Ohashi, Y. Cancer Chemother. Pharmacol. (1992) [Pubmed]
  14. Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract. Pycha, A., Grbovic, M., Posch, B., Schnack, B., Haitel, A., Heinz-Peer, G., Zielinski, C.C., Marberger, M. Urology (1999) [Pubmed]
  15. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Moul, J.W. Eur. Urol. (1999) [Pubmed]
  16. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor. Ichikura, H., Eto, M., Ueno, H., Harada, M., Takayama, K., Tokuda, N., Tatsugami, K., Naito, S. Oncol. Rep. (2006) [Pubmed]
  17. Circumvention of multidrug resistance in genitourinary tumors. van Brussel, J.P., Mickisch, G.H. International journal of urology : official journal of the Japanese Urological Association. (1998) [Pubmed]
  18. The CEA test in urologic cancer: an evaluation and a review. Guinan, P., Dubin, A., Bush, I., Alsheik, H., Ablin, R.J. Oncology (1975) [Pubmed]
  19. Serum beta-2-microglobulin levels in urological cancer. Bunning, R.A., Haworth, S.L., Cooper, E.H. J. Urol. (1979) [Pubmed]
  20. Clinical significance of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in transitional cell cancer. Hirano, Y., Kageyama, S., Ushiyama, T., Suzuki, K., Fujita, K. Cancer Chemother. Pharmacol. (2003) [Pubmed]
  21. p53 autoantibodies in patients with urological tumours. Lang, C., Unteregger, G., Kartarius, S., Günther, J., Bonkhoff, H., Montenarh, M., Zwergel, T. British journal of urology. (1998) [Pubmed]
WikiGenes - Universities